Dicks Sporting Goods Inc vs Twist Bioscience Corp — how do they compare? Dicks Sporting Goods Inc trades at $134.69 (market cap $13.26B), while Twist Bioscience Corp trades at $165.14 (market cap $10.08B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Twist Bioscience Corp for 27 Days on average.
| DKS | TWST | |
|---|---|---|
Market Cap | $13.26B | $10.08B |
Volume | 2,292,035 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $205.00 |
52-Week Low | $121.15 | $25.45 |
Typical Hold Time | 19 Days | 27 Days |
Enterprise Value | $20.31B | $10.01B |
Dividend Yield | 3.71% | — |
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, amid a bearish technical signal and ongoing securities class action news. The stock shows mixed fundamentals with a trailing P/E of 14.86 and P/S of 0.57, while recent earnings beat estimates in two of the last three quarters. Revenue grew to $13.44B in 2025, though net income margin compressed to 3.97% in 2026 trends. Analyst consensus remains positive with a $153.30 price target and 57% buy ratings, but legal overhangs and a negative cash flow trend present headwinds.
The investment case balances attractive valuation multiples against significant litigation risks and weakening profitability. Upside exists if the company navigates legal challenges and stabilizes margins, but the bearish technical setup and negative investor sentiment suggest caution. The stock's near-term direction will likely hinge on Q3 2026 earnings results and developments in the class action lawsuit.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →